Karien C M Gosens, Sjoerd H van der Burg, Marij J P Welters, Sanne Boekestijn, Nikki M Loof, Wim G V Quint, Carel J M van Noesel, Allard C van der Wal, Olivier Richel, Wilhelmus J T A Krebber, Cornelis J M Melief, Henry J C de Vries, Jan M Prins
PURPOSE: Anal cancer is increasing in HIV+ men who have sex with men (MSM). Treatment options for its precursor, high-grade anal intraepithelial neoplasia (HGAIN), are suboptimal. In this phase I to II dose-finding study, we assessed the safety and efficacy of the human papillomavirus type 16 (HPV16) synthetic long peptide vaccine (SLP-HPV-01) in HIV+ MSM with HPV16-positive HGAIN. PATIENTS AND METHODS: Four dosage schedules (1-5-10; 5-10-20; 10-20-40; and 40-40-40-40 μg) of SLP-HPV-01 were administered intradermally with a 3-week interval in 10 patients per dose level (DL)...
October 13, 2023: Clinical Cancer Research